On July 24, MEDBOT-B fell 5.12% in regular trading, trading at 19.94 HKD/share, with turnover of HKD 105 million. The decline comes after the stock surged over 10% in the prior session following a positive profit warning issued on July 22.

The company announced it expects to record its first-ever half-year net profit of RMB 28 million to RMB 40 million for the six months ended June 30, compared with a net loss of RMB 115 million in the year-ago period. Revenue is expected to grow approximately 200% to 230% year over year, driven by strong sales of its Toumai laparoscopic surgical robot, with overseas market revenue surging over 450%. Gross profit margin improved by more than 15 percentage points.

Despite the positive fundamentals, the broader Health Care Equipment sector is under pressure, with MICROPORT down 3.08%, LIFETECH SCI down 5.66%, AK MEDICAL down 2.85%, MICROPORT NEURO down 1.79%, and ANGELALIGN down 1.38%. Market participants have also noted ongoing selling pressure from recently approved full-circulation H-shares and competitive concerns regarding potential pricing moves by industry leader Intuitive Surgical.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)